Last checked at 2 Jan 2018 15:50
For immediate release | 2 January 2018 |
Futura Medical plc
("Futura" or "the Company")
Remuneration of Non-Executive Directors and Total Voting Rights
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces the issue of 37,320 new ordinary shares of 0.2 pence each in respect of the 2017 remuneration of its Non-Executive Directors.
In accordance with the terms of their service agreements, Non-Executive Directors receive approximately 30 per cent of their remuneration in the Company's ordinary shares. For 2017 these were issued at 57.50 pence per share, being the average closing mid-price of the last 10 trading days of 2016 (as announced via RNS on 10 January 2017).
The 37,320 new ordinary shares shall rank pari passu with the existing issued ordinary shares of the Company and have been issued as follows:
Director | Number of ordinary shares issued for 2017 remuneration | Total number of ordinary shares held | Percentage of the Company's issued share capital |
John Clarke | 26,290 | 198,976 | 0.16% |
Jonathan Freeman | 11,030 | 63,565 | 0.05% |
Application has been made to the London Stock Exchange and it is anticipated that trading of the new ordinary shares will commence on AIM at 8:00am on Monday 8 January, 2018.
Immediately following the above issue, the Company will have 120,696,002 ordinary shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 120,696,002 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
The shares element of the Non-Executive Directors' remuneration for 2018 will be awarded at 25.10 pence per ordinary share, being the average closing mid-price of the last 10 trading days of 2017. The Non-Executive Directors will receive these shares at the end of the 2018 financial year.
Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.
For further information please contact:
Futura Medical plc |
James Barder, Chief Executive + 44 (0) 1483 685 670 james.barder@futuramedical.com www.futuramedical.com
|
|
N+1 Singer (Nominated Adviser and Broker)Aubrey Powell / Liz Yong / Jens Ehrenburg+44 (0) 20 7496 3000 |
|
For media enquiries please contact:
|
Buchanan |
Mark Court / Sophie Wills / Stephanie Watson + 44 (0) 20 7466 5000 |
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| John Clarke | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Director/ PDMR | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Futura Medical plc | ||||
b)
| LEI
| 21380053QLT46UNV2303 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p each
GB0033278473 | ||||
b)
| Nature of the transaction
| Issue of shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
e)
| Date of the transaction
| 2 January 2018 | ||||
f)
| Place of the transaction
| Outside of trading venue | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Jonathan Freeman | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Director/ PDMR | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Futura Medical plc | ||||
b)
| LEI
| 21380053QLT46UNV2303 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 0.2p each
GB0033278473 | ||||
b)
| Nature of the transaction
| Issue of shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
e)
| Date of the transaction
| 2 January 2018 | ||||
f)
| Place of the transaction
| Outside of trading venue | ||||